Is the Ki-67 labelling index ready for clinical use?
暂无分享,去创建一个
[1] Johannes Gerdes,et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.
[2] F. Lacombe,et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. , 1991, Cytometry.
[3] M. Fernö,et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. , 1999, Journal of the National Cancer Institute.
[4] M. Fernö,et al. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. , 2001, Human pathology.
[5] A. Luini,et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. , 2003, Journal of the National Cancer Institute.
[6] Yudong D. He,et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. , 2005, Cancer research.
[7] Johannes Gerdes,et al. Ki‐67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells , 2006, Journal of cellular physiology.
[8] Gavin D. Grant,et al. Common markers of proliferation , 2006, Nature Reviews Cancer.
[9] G Hüttmann,et al. Chromophore‐assisted light inactivation of pKi‐67 leads to inhibition of ribosomal RNA synthesis , 2007, Cell proliferation.
[10] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[12] Jingqin Luo,et al. Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.
[13] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[14] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] David Cameron,et al. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? , 2009, European journal of cancer.
[16] A. Di Leo,et al. Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer , 2009, Breast Cancer Research.
[17] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[18] T. Osako,et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis , 2010, Breast cancer.
[19] M. Piccart-Gebhart,et al. Value of Ki67 in breast cancer: the debate is still open. , 2010, The Lancet. Oncology.
[20] M. Dowsett,et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer , 2010, Journal of Clinical Pathology.
[21] M. Cazzaniga,et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.